PYXS — Pyxis Oncology Share News
0.000.00%
Last trade - 00:00- $200.90m
- $167.90m
- $13.86m
U.S. STOCKS ON THE MOVE-RTX, 3M, Invesco
Leerink initiates coverage on Pyxis with 'outperform'; shares rise
Brief: Pyxis Oncology Announces Initiatives To Prioritize Lead Adc Program Reports Financial Results For Third-Quarter 2023 And Provides Corporate Update
Brief: Pyxis Oncology Q3 Net Income USD -23.049 Million
Pyxis Oncology Inc expected to post a loss of 51 cents a share - Earnings Preview
Brief: Pyxis Oncology Successfully Completes Acquisition Of Apexigen
Brief: Pyxis Oncology Q2 basic EPS USD -0.41
Brief: Pyxis Oncology Advances Pyx-106 And Pyx-201 Clinical Programs
U.S. RESEARCH ROUNDUP-Annexon, Nvidia, Southwestern Energy
Apexigen rises on buyout deal with Pyxis Oncology
Brief: Pyxis Oncology To Acquire Apexigen For Total Enterprise Value Of About $16 Million
Brief: Pyxis Oncology Reports Q1 2023 Financial Results And Provides Corporate Update
Brief: Pyxis Oncology Inc Announces Pamela Connealy, CFO, Has Been Promoted To Newly Created Role Of CFO And Chief Operating Officer
Brief: Pyxis Oncology Reports Financial Results For Fiscal Year Ended December 31, 2022
Brief: Pyxis Oncology Announces Dosing Of First Subject In Phase 1 Trial Of Pyx-201, A Novel ADC For Solid Tumors
U.S. STOCKS ON THE MOVE-Silver miners, PVH Corp, energy firms
U.S. STOCKS ON THE MOVE-Gold miners, Kroger, Dollar General, Nutanix
Pyxis Oncology rises on nod for early stage trials of solid tumor drugs
Brief: Pyxis Oncology Announces FDA Clearance Of Two Ind Applications